冷凝集素病
Cold agglutinin disease
定义 英文原文(暂无中文)
Cold agglutinin disease is a type of autoimmune hemolytic anemia defined by the presence of cold autoantibodies (autoantibodies which are active at temperatures below 30°C).
别名
慢性冷凝集素病
基本事实
- 遗传方式
- 多基因/多因素
- 发病年龄
- 成年期
- 患病率
- 1-9 / 1 000 000(Europe)
临床表型 14
极常见 99–80%6
- 关节疼痛 HP:0002829
- 自身免疫 HP:0002960
- 疲乏 HP:0012378
- 溶血性贫血 HP:0001878
- 肌无力 HP:0001324
- 苍白圈 HP:0000980
偶见 29–5%8
- 尿液颜色异常 HP:0012086
- 背部疼痛 HP:0003418
- 腹泻 HP:0002014
- 头痛 HP:0002315
- 肝脏肿大 HP:0002240
- 淋巴结肿大 HP:0002716
- 恶心和呕吐 HP:0002017
- 脾肿大 HP:0001744
近两年的全球研究 329L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-10Evolution of Therapeutic Plasma Exchange Use and Outcomes in Children Across American Society for Apheresis Categories: A Single-Center Cohort Study
- 2026-09病例报告开放获取Case Report: Severe mixed autoimmune hemolytic anemia associated with acute cytomegalovirus infection in an immunocompetent adult
- 2026-09病例报告开放获取Complement inhibition by sutimlimab in cold agglutinin disease promotes red blood cell agglutination and may lead to circulatory complications, eryptosis and hemolysis
- 2026-09综述开放获取Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape
- 2026-09开放获取The impact of chemoimmunotherapy on primary cold agglutinin disease and Waldenström macroglobulinemia-associated cold agglutinin syndrome
- 2026-09Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue
- 2026-09综述开放获取Complement Activation by Post-Translationally Modified Proteins: Links to Chronic Inflammation and Autoimmunity
- 2026-09综述开放获取Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning
- 2026-08开放获取Therapeutic Plasma Exchange Using Membrane Plasma Separation Across a Broad Spectrum of Indications: An Eight-Year Single-Center Retrospective Cohort Study
- 2026-08开放获取Complement-Dominant Relapse of Mixed Autoimmune Hemolytic Anemia After Rituximab Response
- 2026-08Interpretive Challenges in Electrophoretic and Mass Spectrometric Methods for Monoclonal Gammopathy Detection in Patients with Cold Agglutinin Disease
- 2026-08综述开放获取Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape
- 2026-08病例报告开放获取Combination therapy of sutimlimab and rituximab can lead to stable remission in autoimmune hemolytic anemia: a case series
- 2026-08综述开放获取Innate immunity: current understandings and future perspectives
- 2026-08开放获取Effectiveness of the DigniCap® Scalp Cooling System for the Prevention of Chemotherapy-Induced Alopecia: An Observational Study in a Uruguayan Cohort
- 2026-08病例报告开放获取Probable Cold Agglutinin Disease Presenting With Profound Anemia and Cardiopulmonary Decompensation in a 93-Year-Old Woman: A Case Report
- 2026-08病例报告开放获取A blended phenotype of primary immunodeficiency and Temtamy syndrome: Dual homozygosity for <i>STK4</i> and <i>C12orf57</i> gene variants in a Tunisian infant
- 2026-08病例报告开放获取DAT-negative autoimmune hemolytic anemia following acute hepatitis a in a pediatric patient with elevated IgA: a rare case report and literature review
- 2026-08综述开放获取Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non-Japanese Individuals
- 2026-08综述病例报告开放获取Temperature Safeguards and Peri-Procedural Strategies for Stem Cell Collection in Cold Agglutinin Disease: A Case Report and Literature Review
境外已获批用于本病的药物 1L2
欧盟 1 项、美国 0 项。同一药物在两地各批一次的,会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。
药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。
- Enjaymo欧盟2022-11-15sutimlimab官方记录
数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 2L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
登记为可入组 2
- 招募中NCT07019038National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia中国研究中心 1 个:Tianjin
- 尚未开始招募NCT06847607A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)中国研究中心 1 个:Beijing
中国境外的在招试验 6L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
CT.gov 报告命中 6 项,此处取回并展示最近的 4 项。
- 尚未开始招募NCT07091370Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
- 招募中NCT07083960OM336 in Autoimmune Cytopenias澳大利亚、美国
- 招募中NCT05318534Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease英国
- 招募中NCT05931718Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia意大利
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)